Abstract: Objective To observe the clinical efficacy of amlodipine and metformin in combination in the treatment of patients with obese-related hypertension. Methods A total of 102 patients with obese-related hypertension were randomly divided into control group and study group, with 51 cases in each group. The control group was treated with amlodipine, while the study group was added with metformin on the basis of the control group. The clinical effects of the two groups after treatment, andconcentrations of serum total cholesterol(TC), triglyceride(TG), low density lipoprotein(LDL-C), high density lipoprotein( HDL-C), fasting blood glucose(FBG), glycated hemoglobin(HbAlc), as well as fasting insulin(FINS)were compared. The insulin sensitivity index(ISI)was calculated. The body mass index(BMI), waist-hip ratio(WHR)before and after treatment, and occurrence of adverse reactions during the treatment were recorded. Results After treatment, the total effective rate and HDL-C concentration in the study group were significantly higher than those in the control group(P<0.05). Serum TC, TG, LDL-C, FBG, HbAlc, FINS levels, and ISI, BMI, as well as WHR in the study group were significantly lower than those in the control group(P<0.05). The incidence of adverse reactions during treatment was lower in the two groups, and there was no significant difference(P>0.05). Conclusion Compared with metformin alone, the combination of amlodipine and metformin in the treatment of patients with obese-related hypertension has a better clinical effect, which can improve blood lipid level, alleviate obesity and insulin resistance, and has higher safety in medication.